Nchi: Australia
Lugha: Kiingereza
Chanzo: Department of Health (Therapeutic Goods Administration)
meropenem trihydrate, Quantity: 1140 mg
Juno Pharmaceuticals Pty Ltd
Injection, powder for
Excipient Ingredients: sodium carbonate
Intravenous, Intravenous Bolus, Intravenous Infusion
10 vials
(S4) Prescription Only Medicine
Meropenem Juno is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics:,,? Community acquired lower respiratory tract infection ,,? Hospital acquired lower respiratory tract infection,,? Complicated urinary tract infection,,? Febrile neutropaenia,,? Intra-abdominal and gynaecological (poly microbial) infections,,? Complicated skin and skin structure infections,,? Meningitis,,? Septicaemia
Visual Identification: White to light yellow coloured powder.; Container Type: Vial; Container Material: Glass Type III Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius
Registered
2020-07-15
1 MEROPENEM JUNO POWDER FOR INJECTION _Meropenem trihydrate_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Meropenem Juno. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risk of you taking Meropenem Juno against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET. You may need to read it again. WHAT IS MEROPENEM JUNO USED FOR Meropenem is an antibiotic used in adults and children to treat certain serious infections caused by bacteria, such as: • Infections of the lungs • Infections of the kidney or bladder (urinary tract infection) • Febrile neutropaenia • Infections around the stomach or bowel • Infections of the vagina and womb • Serious skin infections • Infections in the lining of the brain (meningitis) • Infections in the blood stream (septicaemia) Meropenem belongs to a group of medicines called carbapenem antibiotics. These medicines work by killing the bacteria that are causing your infection. Meropenem will not work against fungal or viral infections (such as colds or flu). Meropenem is an injection and is usually only used in hospitals. It is available only with a doctor's prescription. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. Meropenem is not addictive. MEROPENEM JUNO IS NOT RECOMMENDED FOR USE IN CHILDREN UNDER THE AGE OF 3 MONTHS. Safety and effectiveness in children younger than 3 months have not been established. BEFORE YOU ARE GIVEN MEROPENEM JUNO WHEN YOU MUST NOT BE GIVEN MEROPENEM JUNO DO NOT USE MEROPENEM JUNO IF YOU HAVE AN ALLERGY TO: • any medicine containing meropenem • any other carbopenems, penicillins or other beta lactam antibiotics • any of the ingredients listed at th Soma hati kamili
Juno Pharmaceuticals Pty Ltd Australian Product Information Page | 1 AUSTRALIAN PRODUCT INFORMATION MEROPENEM JUNO _(MEROPENEM (AS TRIHYDRATE)) _ _ _ 1 NAME OF THE MEDICINE Meropenem, as meropenem trihydrate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Meropenem Juno powder for intravenous injection or infusion 500 mg 1 g Active ingredient Meropenem trihydrate 570 mg 1.14 g Equivalent to anhydrous meropenem 500 mg 1 g Excipient Sodium carbonate 104 mg 208 mg 3 PHARMACEUTICAL FORM Meropenem Juno powder for intravenous injection is presented as a sterile white or light yellow powder containing meropenem trihydrate equivalent to meropenem, 500 mg or 1 g, blended with sodium carbonate. Meropenem Juno powder for intravenous injection contains 208 mg sodium carbonate for each gram of meropenem (anhydrous potency). It contains no preservative. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Meropenem Juno is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: • Community acquired lower respiratory tract infection • Hospital acquired lower respiratory tract infection • Complicated urinary tract infection • Febrile neutropaenia • Intra-abdominal and gynaecological (poly microbial) infections • Complicated skin and skin structure infections • Meningitis • Septicaemia Juno Pharmaceuticals Pty Ltd Australian Product Information Page | 2 4.2 DOSE AND METHOD OF ADMINISTRATION TREATMENT ADULTS Usual dose 500 mg to 1 g by intravenous administration every 8 hours depending on type and severity of infection, the known or suspected susceptibility of the pathogen(s) and the condition of the patient. Exceptions 1. Febrile episodes in neutropaenic patients - the dose should be 1 g every 8 hours. 2. Meningitis - the dose should be 2 g every 8 hours. As with other antibiotics, caution may be required in using meropenem as monotherapy in critically ill patients with known or Soma hati kamili